Optimal Treatment of Hidradenitis Suppurativa

Friday, March 17

This symposium explores best practices in the treatment of hidradenitis suppurativa (HS), focusing on high-priority educational topics that were identified in a multi-stakeholder advisory board meeting conducted by Novartis Dermatology Medical Affairs in November 2022. The symposium consists of 5 consecutive short presentations on the following topics:

  • General clinical strategies and guidance regarding biologic use in HS
  • Unmet needs in HS treatment and the “window of opportunity” concept
  • Understanding the heterogeneity of HS severity and the challenge of defining “moderate” HS
  • Approaches to documenting HS for payers and streamlining prior authorization of HS treatments
  • The role of the HS Foundation in overcoming challenges and barriers faced by HS patient

When: Friday, March 17 | 6:30 p.m. Registration | 7 p.m. Program
Where: Cypress Ballroom | Marriott Warehouse Arts District Hotel

Novartis Logo Pos Rgb